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Abstract. The P75 neurotrophin receptor (p75NTR) is a cell
surface receptor that can induce apoptosis in many cell types.
This receptor plays a major role in the development of the
central nervous system and is expressed in some adult brain
cells. Its implication in cell apoptosis or survival is probably
of major importance in cellular homeostasis and thus p75NTR
could be implicated in tumor resistance to death. In this
study, we investigated the intracellular expression of p75NTR
in a human glioblastoma cell line. Detection of p75NTR receptor
in Golgi apparatus by immunofluorescence microscopy, or
after Golgi apparatus extraction, could be correlated with a
decrease of cell apoptosis leading cells to become tumorous.
This hypothesis is supported by a loss of ligand-induced
apoptosis in this cell line. Our observations show that p75NTR
can be sequestered in the Golgi complex and could then be,
in part, responsible for the cell resistance to apoptosis and for
brain tumor formation.
Introduction
The neurotrophins (NT) such as nerve growth factor (NGF),
brain-derived neurotrophic factor (BDNF), NT-3 and -4,
use a two receptor system to promote cell differentiation,
survival or cell death by apoptosis. These receptors are the low
affinity neurotrophin receptor p75 (p75NTR) and the tyrosine
kinase receptor (Trk) family. Each NT is specific for a Trk
receptor, but all bind the p75NTR with comparable affinities
(1). P75NTR is a glycoprotein that belongs to the tumor necrosis
factor/nerve growth factor receptor family (TNFR/NGFR).
This receptor is a type I transmembrane protein that contains
an extracellular and an intracellular domain. The extracellular
domain contains 4 repetitions of a 40-amino acid cysteine
rich sequence, that can bind all of the four NTs, and a serine-
threonine rich domain. The intracellular portion includes a
death domain (2) and potential adaptator molecule-associated
domains (3). NT interaction with cystein-rich domain of
p75NTR induces different transduction pathways such as c-Jun
N-terminal kinase (JNK) activation (4-6), sphingomyelin
hydrolysis (7), nuclear transcription factor NF-κB activation
(8), caspase pathway activation (9,10), activation of cell cycle
regulatory molecules (11,12) and p53 activation (13), leading
to apoptosis, survival, differentiation or cell cycle regulation.
P75NTR is a glycoprotein of 75 kDa when all post-trans-
ductional modifications are added. Phosphorylation occurs
on serine and threonine residues and may regulate receptor
multimerization (14,15) and palmitoylation happens on
cysteine 279 (16). Glycosylation of the receptor consists in a
single asparagine-linked carbohydrate at position 33 located
in the first cysteine repeat and several O-linked carbohydrates
in the juxtamembrane stalk domain (17,18). These post-
traductional modifications take place in endoplasmic reticulum
and Golgi apparatus.
The Golgi apparatus is a series of flattened, cisternal
membrane structures forming the heart of the secretory
pathway. The Golgi stack is a polarized structure with a
cis-face, the cis-Golgi network (CGN), exchanging proteins
and lipids with the endoplasmic reticulum (ER), and a trans-
face, the trans-Golgi network (TGN), communicating with
the plasma membrane and compartments of the endocytic
pathway. As secretory materials pass through the Golgi in a
cis to trans fashion, it becomes post-translationally modified
in a sequential order before being sorted at the TGN for
delivery to its final destination within the cell (19).
P75NTR isoforms have been detected. They are produced
both by alternative splicing and proteolysis. One splice variant
of p75NTR consisted in only lost of the first cystein-rich repeat
in its extracellular domain (20). The splicing of the third
exon of the p75NTR transcript generated a variant that did
not bind any of the NT because of the lack of cystein-rich
domains 2, 3 and 4 but that could interfere with signaling
transduction pathways. Full-length p75NTR can also be cleaved
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by a constitutively active metalloproteinase to generate a
soluble extracellular domain that is capable of binding neuro-
trophins and a receptor fragment containing the transmembrane
and intracellular domains (21-23).
P75NTR is a protein that is traditionally detected at the cell
surface. Recently, involvement of p75NTR in lipid rafts was
shown and its contribution in signaling transduction confirmed
(24). Lipid rafts concentrate lipids and proteins that function in
transmembrane signaling events, allowing them to interact with
each other and preventing them for interacting with molecules
excluded from rafts. We studied the expression of p75NTR
protein in the Golgi apparatus of U-87-MG cells and the
effects of neurotrophin treatments on this localization. We
also studied the consequence of this sequestration on the
apoptosis induced by a specific p75NTR ligand.
Materials and methods
Cell line culture. Human glioblastoma cells U-87 MG (ATCC,
Manassas, VA) were cultured in MEM with Earl' salts
(Gibco BRL, Cergy Pontoise, France) supplemented with
10% decomplemented fetal calf serum (FCS), 1.5 g/l sodium
bicarbonate, 1% non-essential amino acids, sodium pyruvate
(2 mM), penicillin (50 U/ml), streptomycin (50 U/ml), L-
glutamine (2 mM) and fungizone (0.1%) (Gibco BRL).
Cells were grown in a 25 cm2 flask (Sarstedt, Orsay,
France) at 37˚C in a humidified 5% CO2-95% air incubator.
At sub-confluence, cells were recovered with versene (Gibco
BRL) and cultured in Lab-Tek chamber slides at 104 cells per
well for immunocytochemistry or in 96-well plates at 104
cells per well for apoptosis detection assays (Nunc, VWR,
Strasbourg, France).
After 3 days in culture, different molecules were added
prior to immunocytochemistry or functional assays: a human
recombinant ß NGF (50 μM, ICN Biomedical, Irvine, CA), a
human recombinant BDNF (50 μM, Promega, Charbonnières,
France), a mouse anti-p75NTR monoclonal antibody (anti-p75
mAb) without sodium azide (50 μM, clone NGFR5,
NeoMarkers, Fremont, CA, USA) for 48 h, Brefeldin-A
(BFA, 10 μg/ml, Sigma-Aldrich, Saint-Quentin Fallavier,
France) for 2 h, or nordihydroguaiaretic acid (NDGA, 10 μM,
Sigma-Aldrich) for 24 h. BFA is a fungal derived-substance
known to cause apoptosis in different cell lines (25) by
promoting retrogradous protein transport from the Golgi
apparatus to the endoplasmic reticulum and that leads
different components of Golgi complex to redistribute in a
characteristic manner in all the cells (26-28). NDGA, known
as a dual inhibitor for lipooxygenases and cyclooxygenases,
inhibits the transport assay but also causes disassembly of the
Golgi apparatus (29).
Immunofluorescence assays. In order to analyse receptors
and ligands localisation, cell cultures were labeled at basal
state or after exposure to BFA, NDGA, NGF or BDNF. Cells
were fixed in 4% paraformaldehyde (Sigma-Aldrich) in PBS
for 30 min at room temperature (RT) and permeabilized
using alcool/acetone (v/v) for 5 min on ice. After a 90-min
saturation at RT with 10% goat serum (Sigma-Aldrich) in PBS,
cells were incubated for 90 min at RT with primary antibodies
diluted in saturating solution: anti-p75NTR monoclonal antibody,
1/100 (clone NGFR5) and anti-p75NTR rabbit polyclonal
antibody, 1/50 (anti-p75 ntAb, H-137, Santa Cruz Biotechno-
logy, CA, USA) that both recognize the extracellular domain,
anti-p75NTR rabbit polyclonal antibody, 1/50 (anti-p75NTR ctAb,
H-92, Santa Cruz Biotechnology) that binds the intracellular
domain, anti-mannosidase II rabbit antiserum, 1/200 [manno-
sidase II was shown to be a protein exclusively expressed in
Golgi (30), Chemicon International, CA, USA], anti-golgin-97
mouse monoclonal antibody, 1/250 (clone CDF4, Molecular
Probes, Leiden, The Netherlands), anti-TrkA mouse mono-
clonal antibody, 1/50 (clone 165131, R&D Systems, Minnea-
polis, MN, USA), anti-TrkB mouse monoclonal antibody, 1/50
(clone 72509, R&D Systems), anti-BDNF rabbit polyclonal
antibody, 1/100 (Santa Cruz Biotechnology), anti-NGF rabbit
polyclonal antibody, 1/100 (Santa Cruz Biotechnology). They
were then revealed by a 30-min incubation with Alexa Fluor
488-conjugated goat anti-rabbit immunoglobulin (Ig) antibody
(1/6000, Molecular Probes) and Alexa Fluor 594-conjugated
goat anti-mouse Ig antibody (1/6000, Molecular Probes).
Lipid rafts were detected with a cholera toxin B subunit FITC-
conjugated (Sigma-Aldrich), incubated during 20 min at 4˚C,
at 1/200 in PBS. Cells were fixed with glycerol gelatin
(Sigma-Aldrich) and examined by confocal microscopy
(Carl Zeiss S.A.S, LSM 510, Jena, Germany). Isotypic controls
were realised using mouse IgG (Diaclone, Besançon, France)
or rabbit Ig fraction (Dako Cytomation, Trappes, France).
Subcellular fractionation. Cells were washed twice in PBS and
once in homogenization medium. After being resuspended in
homogenization medium, cells were disrupted by 15 strokes
in a Dounce homogenizer. Nuclei and unbroken cells were
pelleted by centrifugation at 2000 g for 10 min. Discontinuous
Iodixanol gradients were made according to Graham et al (31)
with some modifications. Iodixanol was diluted to a final
concentration of 50% Iodixanol, 0.25 M sucrose, 1 mM EDTA,
and 10 mM HEPES, pH 7.4, as the gradient stock solution.
Different densities of Iodixanol were established by diluting
this stock with 0.25 M sucrose homogenization buffer.
Gradients were then set up in 13 ml Beckman SW41 centrifuge
tubes by underlayering with a syringe and metal needle as
follows: 2.5% Iodixanol, 1 ml; 5%, 2 ml; 7.5%, 2 ml; 10%,
2 ml; 12.5%, 0.5 ml; 15%, 2 ml; 17.5%, 0.5 ml; 20%, 0.5 ml;
and 30%, 0.3 ml. The vesicle fractions were loaded on top of
the gradients and centrifuged in a SW41 rotor at 40,000 rpm
for 2.5 h (4˚C). The resulting gradient was collected in 500 μl
fractions. Iodixanol gradient material (OptiPrep, 60% w/v)
was purchased from Sigma-Aldrich.
Fractions rich in Mannosidase II activity (32) (not shown),
an enzyme selectively localized into Golgi vesicles, were
centrifuged at 20,000 g for 30 min. The pellet obtained was
resuspended in PBS with 0.25% Triton X-100.
Endoglycosidase digestion. Cells were washed once with PBS
and lysed in appropriate buffer [PBS, 0.25% Triton X-100,
1 mM phenylmethylsulfoxyfluoride, 1 μg/ml aprotinin, 1 μg/ml
pepstatin A, 1 μg/ml leupeptin, 1 mM NaF and 1 mM NaV3O4
(Protease inhibitor cocktail set III, Calbiochem)]. After
centrifugation at 14,000 g for 15 min at 4˚C, supernatants
were collected. Protein concentrations were determined by
the Bradford method (33) (Bio-Rad, Hercules, CA).
GIRAUD et al:  P75 CAN BE SEQUESTRATED392
391-399.qxd  22/12/2010  10:18 Ì  ™ÂÏ›‰·392
After denaturation, deglycosylation of 100 μg of proteins
was achieved by addition of 5 U of peptide-N-glycosidase F
(EC 3.5.1.52, Sigma-Aldrich) or 0.04 U of O-glycosidase
(EC 3.2.1.97, Sigma-Aldrich) and 1 U of neuraminidase (EC
3.2.1.18, Sigma-Aldrich), with adequate buffers, according to
the manufacturer. Digests were incubated at 37˚C overnight.
Western blot analysis. Proteins (20 μg) were boiled for 5 min
in Laemmli buffer, separated by electrophoresis on NuPAGE
4-12% Bis-Tris Gel (Invitrogen, Carlsbad, CA, USA) and
transferred to nitrocellulose sheets (HAHY 0.45 μM,
Millipore, St Quentin-Yvelines, France). After saturation
with 5% non-fat dried milk in PBS, the sheets were incubated
overnight at 4˚C with anti-p75 mAb (1/200, NGFR5) diluted
in 1.5% bovine serum albumin (Jacques Boy Institute S.A.,
Reims, France) in PBS and with mouse IgG1 (Diaclone) as
isotypic control. After three washes in PBS and a 1-h
incubation with an anti-mouse Ig peroxidase-labelled goat
antiserum (1/1 000, Dako Cytomation), the sheets were
revealed by the Covalight enhanced chemiluminescence
procedure (AbCys, Paris, France).
Flow cytometry analysis. Cells were released from the flask
with versene, permeabilized or not with Triton X-100 for 5 min
at 4˚C and resuspended in 10% FCS in versene with mouse
anti-p75NTR monoclonal antibody (NGFR5) diluted at 1/40 or
mouse IgG1 Ig (Diaclone) as isotypic control. After a 30-
min incubation on ice, antibodies were detected with a
goat anti-mouse Ig FITC-conjugated antibody (Dako
Cytomation) diluted at 1/100 in 10% FCS in versene during
30 min, on ice. Finally, cells were resuspended and fixed in
10% FCS/1% paraformaldehyde in versene.
Each analysis was performed on at least 20,000 cells and
repeated thrice. Relative fluorescence intensity was measured
by fluorescence-activated cell sorter analysis (Epics XLMCL
Coulter, Hialeah, FL, USA). Mean fluorescence intensity
(MFI) was the mean of the three independent experiments.
Apoptosis detection by cell death detection ELISA plus. Cell
apoptosis was evaluated using cell death detection ELISA
plus (Roche Diagnostic, Meylan, France). Cells were
seeded in wells of 96-multiwell plates (104 cells/well) and
maintained in culture 3 days. After a 48-h stimulation with an
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Figure 1. P75NTR receptor was detected in Golgi apparatus by confocal microscopy. (A) Double-staining was performed with a mouse anti-p75NTR monoclonal
antibody (anti-p75NTR mAb) and a rabbit anti-mannosidase II antibody (anti-Golgi Ab) on U-87 MG cell line (left panel). P75NTR labelings were next realized
with two polyclonal antibodies recognizing N-terminus domain (anti-p75NTR ntAb) and C-terminus domain (anti-p75NTR ctAb) of the protein (right pannel).
Primary antibodies were revealed by a goat anti-mouse Alexa Fluor 594-conjugated and a goat anti-rabbit Alexa Fluor 594 or 488-conjugated antibody. (B)
U-87 MG cells were permeabilized or not, and stained with an anti-p75NTR mAb and goat anti-mouse Ig FITC-conjugated antibody and analyzed by flow
cytometry. Mean fluorescence intensity (MFI), representative of 3 experiments, is indicated for each labelling and isotypic control was superimposed (in grey).
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anti-p75NTR mAb, rate of apoptosis was measured using cell
death detection ELISA plus according to the manufacturer's
instructions. This method differentiates the late apoptotic
and necrotic cells. This ELISA simultaneously uses two
monoclonal antibodies against DNA and histones to allow
the specific detection of mono- and oligo-nucleosomes in the
cytoplasmic fraction, characteristic for apoptosis. Absorbance
values were measured at 405 nm with ELISA reader (Packard
Instruments, Meriden, USA). Results were from three inde-
pendent experiments.
Terminal transferase (TdT)-mediated dUTP nick-end labeling
(TUNEL) assays. After a 48-h stimulation, cultured cells were
fixed with 4% paraformaldehyde diluted in PBS for 30 min at
room temperature, permeabilized with 0.1% Triton X-100
during 5 min at 4˚C and stained by the TUNEL method with
FITC labelling as described by the manufacturer (Promega)
for 1 h at 37˚C. Reaction was stopped by a 10-min wash in salt
sodium citrate 2X and cells were counterstained with Evans'
blue (Sigma-Aldrich). Cells were counted by fluorescence
microscopy (Carl Zeiss S.A.S) with a magnification x200
(a minimum of 600 cells from 3 fields were counted for each
conditions). Each assay was repeated thrice. Statistical
analysis was performed using the t-test. A p<0.05 was
considered as statistically significant.
Results
P75NTR protein is detected in Golgi apparatus. Immunocyto-
chemical studies were performed with anti-p75NTR antibodies
on U-87 MG cells (Fig. 1A). The p75NTR receptor was detected
in the Golgi apparatus as confirmed by double-staining with
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Figure 2. P75NTR immunolabelling is homogeneous in the cytoplasm of BFA and NDGA-treated cells. Double-staining was realized with a mouse anti-p75NTR
monoclonal antibody (anti-p75NTR mAb) and a rabbit anti-mannosidase II antibody (anti-Golgi Ab) on U-87 MG cell line, after treatments with BFA and
NDGA, molecules that disrupt Golgi apparatus. A goat anti-mouse Alexa Fluor 594-conjugated and a goat anti-rabbit Alexa Fluor 488-conjugated antibody
revealed the primary antibodies.
Figure 3. P75NTR is not present in lipid rafts of U87-MG cells. P75NTR labeling with a mouse anti-p75NTR monoclonal antibody (anti-p75NTR mAb) was
observed on U-87 MG cells associated with raft labelling by cholera toxin B subunit FITC-conjugated. A goat anti-mouse Alexa Fluor 594-conjugated
antibody revealed the primary antibody.
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anti-p75NTR mAb and anti-mannosidase II antibodies (anti-
Golgi Ab). The p75NTR protein, near the nucleus, was detected
with both anti-p75NTR polyclonal antibodies, recognizing the
N-terminsal part of the protein (anti-p75NTR ntAb) and the
C-terminus part (anti-p75NTR ctAb).
A p75NTR cell surface labelling was also detected by
immunocytochemistry (Fig. 1A) and confirmed by flow
cytometry (Fig. 1B), with the anti-p75NTR mAb (clone NGFR5)
on U-87 MG cells. While p75NTR receptor was generally
detected into the cells (MFI = 0.280±0.095, not detected when
cells were not permeabilized), only 3% of U-87 MG cells
expressed the p75NTR receptor at cell surface (MFI = 41.9±5.8,
Fig. 1B). Isotypic control (in grey) was realised and super-
imposed with immunolabelling.
BFA and NDGA disrupt Golgi apparatus and p75NTR labelling.
Both molecules, BFA and NDGA, that degrade the Golgi
apparatus disrupted Golgi and p75NTR labelling in U-87 MG
cell lines (Fig. 2), confirming that the protein detected by the
anti-p75NTR antibodies was truly expressed in Golgi apparatus.
P75NTR protein is not located in lipid rafts. Anti-p75NTR mAb
and Raft double-stainings were performed on U-87 MG cell
line, but no correlation could be observed, as no super-
imposable staining patterns were detected in cells expressing
p75NTR at cell surface (Fig. 3).
The 75-kDa mature form of p75NTR protein is present in Golgi
apparatus. Molecular weights of proteins recognized by
anti-p75NTR antibody were analyzed by Western blotting on
U-87 MG cell line (Fig. 4). Different proteins were detected.
Without enzymatic digestion (Fig. 4), 75 and 53.4 kDa
proteins were detected. A 56.6- kDa protein was occasionally
detected (Fig. 4B). Endoglycosidase digestions of the total
cell lysate showed that the 75 kDa form of the protein is N-
and O-glycosylated. The 56.6-kDa form appeared to be only
N-glycosylated, whereas the 53.4-kDa form seemed to be
neither O- nor N-glycosylated.
After Golgi apparatus extraction, Western blot analysis of
proteins showed that the three forms of the p75NTR protein
were present in Golgi apparatus (Fig. 4B). Isotypic controls
were realized in order to verify non-specific labelling and no
staining was observed (not shown).
Detection of TrkA, TrkB, NGF and BDNF in U-87 MG cells.
Immunocytochemical studies were performed with anti-TrkA,
-TrkB, -NGF and -BDNF antibodies on U-87 MG cells
(Fig. 5A). TrkA and NGF were detected in the cells, whereas
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Figure 4. The 75 kDa mature form of p75NTR protein is present in Golgi
apparatus. (A) U-87 MG cells were lysed, proteins were digested by N- and
O-glycosidases, then separated on NuPAGE 4-12% Bis-Tris Gel, transferred
onto nitrocellulose sheets and detected using a mouse anti-p75NTR monoclonal
antibody (anti-p75NTR mAb) or with mouse IgG1 Ig as isotypic controls (not
shown). (B) After subcellular fractionation on discontinuous Iodixanol
gradients, proteins of Golgi apparatus containing fractions were separated
on NuPAGE 4-12% Bis-Tris Gel, transferred onto nitrocellulose sheets and
detected using a mouse anti-p75NTR monoclonal antibody (anti-p75NTR mAb)
or with mouse IgG1 Ig as isotypic controls (not shown).
Figure 5. Presence of TrkA, TrkB, NGF and BDNF in U-87 MG cells. (A)
Immunocytochemicals studies were performed with mouse anti-TrkA and
-TrkB monoclonal antibodies, rabbit anti-NGF and -BDNF polyclonal
antibodies on U-87 MG cells in basal condition. (B) Double-stainings were
realized with a rabbit anti-BDNF polyclonal antibody and a mouse anti-Golgi
antibody (anti-Golgi Ab) on U-87 MG cells in basal condition. In (A) and
(B), a goat anti-mouse Alexa Fluor 594-conjugated and a goat anti-rabbit
Alexa Fluor 488-conjugated antibody revealed the primary antibodies.
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TrkB was also detected at cell membrane, and BDNF in
Golgi apparatus (as confirmed by double-staining with anti-
BDNF and anti-Golgin antibodies, see Fig. 5B). 
BDNF modifies the p75NTR receptor cell surface expression.
The U-87 MG cell line was treated with NGF and BDNF for
48 h. While NGF had no effect on p75NTR protein localization
in Golgi apparatus, BDNF changed its cell surface expression
(Fig. 6A). Indeed, p75NTR protein quantity in cell extensions
seemed to be increased when cells were observed by
immunofluorescence (Fig. 6B).
BDNF does not modify BDNF, TrkA and TrkB cell location.
The U-87 MG cell line was treated with BDNF for 48 h and
double-staining immunocytochemicals studies were
performed with anti-BDNF and anti-p75NTR antibodies, or
with anti-TrkA and anti-p75NTR antibodies, or with anti-TrkB
and and anti-p75NTR antibodies (Fig. 7). BDNF treatment
had no effect on BDNF, TrkA and TrkB location, compared
to basal. BDNF effect on p75NTR cell surface expression
decribed above was confirmed.
After BDNF treatment, p75NTR protein is not co-localised
with TrkB. After BDNF treatment, no correlation could be
observed between p75NTR and TrkB cell surface expression
(Fig. 7C).
Apoptosis detection of cell lines submitted to p75NTR mAb
treatments. The anti-p75 mAb (clone NGFR5) effect on the
U-87 MG cell line was analysed by both TUNEL and cell
death detection ELISA plus methods (Fig. 8). Thus, whatever
the method, no apoptosis variation was detected (p>0.3 for
all comparisons).
Discussion
P75NTR protein was usually detected at cell surface. In this
report, this receptor has been localized in the Golgi apparatus
GIRAUD et al:  P75 CAN BE SEQUESTRATED396
Figure 6. Studies of p75NTR cell surface expression after NGF and BDNF treatments. (A) Double-stainings were realized with a mouse anti-p75NTR monoclonal
antibody (anti-p75NTR mAb) and a rabbit anti-mannosidase II antibody (anti-Golgi Ab) on U-87 MG cells after NGF or BDNF treatments. (B) P75NTR labeling
with a mouse anti-p75NTR monoclonal antibody (anti-p75NTR mAb) was observed on U-87 MG cells with or without BDNF and with a smaller magnification. A
goat anti-mouse Alexa Fluor 594-conjugated and a goat anti-rabbit Alexa Fluor 488-conjugated antibody revealed the primary antibodies.
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of U-87 MG cells. Indeed, p75NTR immunolabelling showed
strong staining near the nucleus, suggesting that p75NTR
protein was localized in the Golgi apparatus. This hypothesis
was confirmed by double-staining with both anti-p75NTR and
anti-Golgi antibody, as they stained the same area of cells.
Furthermore, p75NTR labelling was modified when cells
were submitted to molecules that degrade Golgi apparatus,
confirming that p75NTR protein was truly localized in the Golgi
apparatus. The use of polyclonal antibodies that recognized
respectively p75NTR N- and C-terminus domains, confirmed
these results and suggested that p75NTR is present in Golgi
apparatus in it full length form. Nevertheless, some U-87 MG
cells expressed p75NTR at the cell surface, but at low rate.
The analysis of p75NTR molecular weight by Western
blotting showed three main bands. Deglycosylation analysis
demonstrates that the 53.4-kDa protein corresponded to
p75NTR receptor without N- and O-glycosylation, the 56.6 kDa
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Figure 7. BDNF effects on BDNF, TrkA and TrkB cell location is compared with p75NTR cell surface expression. After BDNF cell line treatment (48 h),
double-staining immunocytochemicals studies were performed with a rabbit anti-BDNF polyclonal and a mouse anti-p75NTR monoclonal antibodies (A), with
a mouse anti-TrkA monoclonal and a rabbit anti-p75NTR polyclonal antibodies (B), and with a mouse anti-TrkB monoclonal and a rabbit anti-p75NTR
polyclonal antibodies (C). A goat anti-mouse Alexa Fluor 594-conjugated and a goat anti-rabbit Alexa Fluor 488-conjugated antibody revealed the primary
antibodies.
Figure 8. P75NTR activation did not change the apoptotic level of U87-MG
cells. Apoptotic level of U87-MG cells after anti-p75NTR monoclonal antibody
exposure for 48 h were determined by cell death detection ELISA plus and
TUNEL methods.
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to the N-glycosylated form and the 75 kDa to the mature
receptor. Yeaman et al (34) showed that N-glycans are not
necessary for sorting of p75NTR at MDCK cell membrane, and
that structural information for apical sorting of the receptor at
membrane is localized to a juxtamembrane region of the
extracellular domain that is rich in O-glycosylated
serine/threonine residues. However, in our study, the mature
O-glycosylated form of p75NTR protein is localized in Golgi
apparatus. Moreover, O-glycosylation was shown to be
crucial for protein cell surface expression and may regulate
association with rafts (35). In contrast with this result, no
clear relation between p75NTR cell surface receptors and raft
localization could be pointed out in U87-MG cells. As p75NTR
phosphorylation was described to be implicated in p75NTR
lipid raft localization (36), it would be interesting to study
p75NTR phosphorylation in U87-MG cell line. Otherwise, the
presence of O-glycosylations is a prerequisite for exit from
the ER and protection from intracellular cleavage of p75NTR
(35). The data are in accordance with the presence of the full
length and O-glycosylated form of p75NTR in Golgi complex
of U87-MG cells, as demonstrated in our study.
The localization of the neurotrophins NGF and BDNF
and their receptors, TrkA and TrkB, were studied in U-87
MG cells. Interestingly, as p75NTR receptor, BDNF was
detected in Golgi apparatus and could be the result of their
internalization. Indeed, internalization of neurotrophins and
their receptors are well documented. Kahle and Hertel (37)
presented evidence that rat glial cells are able to sequester
NGF from the cell surface to an intracellular compartment,
and that p75NTR may mediate this internalization. Moreover,
Bronfman et al (38) showed a ligand-induced internalization
of the p75NTR receptor in PC12 cells. In their model, both
internalized ligand and receptor were protected from proteolytic
degradation and accumulated in vesicles that did not undergo
acidification. Alderson et al (39) demonstrated that cultured
hippocampal astrocytes and schwann cells specifically bind
and internalize BDNF and NT-4/5. Moreover, they showed
that a substantial portion of the endocytosed pool of neuro-
trophins is released back into the extracellular medium
without obvious degradation. In retinal ganglion cells, NT-3,
NGF and BDNF accumulate transiently in the Golgi system
(40). The NT-3 lysosomal pathway and the anterograde
transport from Golgi apparatus involve binding to the p75NTR
receptor. Taken together, these data are consistent with the
presence of BDNF and p75NTR in the Golgi apparatus of U-87
MG cells, as demonstrated in our study. Since TrkB was
present at U-87 MG cell surface as well as in the cytosol, this
receptor could be involved in BDNF internalization.
Thus, in U-87 MG cells, p75NTR protein is sequestered in
the Golgi complex and not fully expressed at the cell surface.
Like this receptor, two proteins belonging to the TNF receptor
superfamily were reported to be detected in the Golgi
apparatus. CD95 (Fas) membrane expression was shown to
be regulated by sequestration in the Golgi complex in B-cell
lymphoma (41). Moreover, Bradley et al (42) showed that
55 kDa, but not 75 kDa, TNF receptors were predominantly
localized in the Golgi apparatus of endothelial cells. As for
Fas receptor, p75NTR retention in the Golgi complex may
therefore be an important mechanism for preventing p75NTR
cell surface expression in glial cells, which may be of direct
relevance for brain tumor pathogenesis. This hypothesis
seems to be confirmed by the fact that treatment with the
anti-p75NTR mAb did not increase the cell apoptotic rate of
U-87 MG cells, while p75NTR protein is reported to be a pro-
apoptotic receptor in glioblastoma cell line (43,44). This
receptor sequestration may be a way for tumor cells to escape
from apoptosis due to neurotrophin binding. Thus, induction
of p75NTR expression on cell surface might be an interesting
way to improve tumor apoptosis.
In order to study the effects of p75NTR classical ligands,
NGF and BDNF, we first tested the presence at cell surface of
the neurotrophin receptors TrkA and TrkB in U-87 MG cells.
The fact that NGF treatment did not change the expression
pattern of p75NTR is in accordance with the absence of TrkA
at U-87 MG cell surface. However, BDNF treatment seemed
to increase the p75NTR receptor cell surface expression, which
might be promoted by the presence of TrkB at cell surface.
Bennett et al (45) showed that Fas is sequestered in Golgi
apparatus of human vascular smooth muscle cells. Interestingly,
p53 activation transiently increases Fas surface expression by
transport from the Golgi complex. Moreover, p53-induced
apoptosis of these cells requires surface transport of the
receptor. Contrary to Fas which targets the cell surface
during pro-apoptotic treatment in this model, p75NTR in U-87
MG cells studied seemed here to require differentiation and
proliferation factor (as BDNF) for targeting the cell surface.
Thus, it would be of interest to submit U-87 MG cells to Fas-
L treatment or other apoptosis inducing molecules, and to
study eventual redistribution of p75NTR. Considering that the
decision of cell survival or death depends on the presence or
absence of Trk receptors coexpressed with p75NTR at cell
surface (46), we looked for their eventual colocation after
BDNF treatment: no correlation could be established
between p75NTR and TrkB or TrkA cell surface locations.
Thus, whether this redistribution of p75NTR at cell surface
represents a pathway for differentiation, proliferation or
death of U-87 MG cells remains to be clarified.
Intracellular sequestration of death receptors, like
p75NTR in U87-MG cells, may cause resistance to apoptosis
and insensitivity to chemotherapeutic agents for cancer.
Conversely, a therapy based on cell surface redistribution
of death receptors through endogenous ligands remains to be
studied, but also requires the understanding of the consequent
signaling pathways.
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